Product Information
CHLORDIAZEPOXIDE-CLIDINIUM CAP is a generic product labeled by Micro Labs Limited, priced at $0.2561 per EA under NDC 42571038101. Its NADAC has been published 160 times since Sep 13, 2023.
FDA first approved this application on Jul 19, 2022. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.
Strength
5; 2.5 mg/1; mg/1
Manufacturer
Micro Labs LimitedNDC
42571038101
Classification
Generic
Dosage Form
CAPSULE
Route
ORAL
Effective Date
9/23/2026
Active Ingredients
CHLORDIAZEPOXIDE HYDROCHLORIDE; CLIDINIUM BROMIDEApproval Type
Generic (ANDA)
FDA Application
ANDA215835FDA Approved
7/19/2022
TE Code
AB
On Market Since
10/1/2022
Pharmacological Classes
Price Statistics
The NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has been published 160 times since Sep 13, 2023, and over the history we have for it it has held within roughly two percent of its current level. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.2561 per EA |
|---|---|
| All-time high | $0.5272 (Oct 16, 2024) |
| All-time low | $0.2405 (Mar 18, 2026) |
| 52-week high | $0.3051 |
| 52-week low | $0.2405 |
| Median price | $0.2940 |
| Average price | $0.3128 |
| Largest weekly change | +78.0% (Aug 21, 2024) |
| Weeks tracked | 160 |
| Tracking since | Sep 13, 2023 |
Generic Alternatives
No other NADAC-published product shares this drug's active ingredient and strength in a comparable dosage form. Compare the broader picture on the CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE market page.
Lowest-Cost Alternatives
No alternatives available
Related Drugs
Same classification
Continue researching this drug
Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.
Manufacturer
Micro Labs Limited manufacturer profile
See the full portfolio, pricing trend, and other products from this labeler.
Drug market
CHLORDIAZEPOXIDE HCL AND CLIDINIUM BROMIDE market comparison
Compare this molecule across participating manufacturers and inspect the broader market price spread.
Therapeutic class
Anticholinergic class view
See how this drug behaves alongside other products in the same FDA pharmacologic class.
Trend hub
Latest market trends
Zoom back out to the weekly mover view and compare this NDC with the rest of the current NADAC release.
Guide
Understanding NADAC pricing
Use the explainer when you need context on how CMS publishes NADAC and how to interpret the number on this page.
Frequently asked questions
What is the NADAC price of CHLORDIAZEPOXIDE-CLIDINIUM CAP?
The current National Average Drug Acquisition Cost (NADAC) for CHLORDIAZEPOXIDE-CLIDINIUM CAP, manufactured by Micro Labs Limited, is $0.2561 per EA (NDC 42571038101), effective Sep 30, 2026.
How has the price of CHLORDIAZEPOXIDE-CLIDINIUM CAP changed over time?
Over the history we have for it, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has held within roughly two percent of its current level. It has been tracked across 160 weekly CMS publications since Sep 13, 2023.
What are the highest and lowest recorded NADAC prices for CHLORDIAZEPOXIDE-CLIDINIUM CAP?
Since Sep 13, 2023, the NADAC for CHLORDIAZEPOXIDE-CLIDINIUM CAP has ranged from a low of $0.2405 (Mar 18, 2026) to a high of $0.5272 (Oct 16, 2024), with a median of $0.2940 per EA.
Are there cheaper alternatives to CHLORDIAZEPOXIDE-CLIDINIUM CAP?
No other NADAC-published product currently shares the active ingredient and strength of CHLORDIAZEPOXIDE-CLIDINIUM CAP in a comparable dosage form, so no direct lower-cost alternative is listed.
Who manufactures CHLORDIAZEPOXIDE-CLIDINIUM CAP?
CHLORDIAZEPOXIDE-CLIDINIUM CAP (NDC 42571038101) is labeled by Micro Labs Limited, and CMS classifies it as a generic product.